A Nature Medicine news feature floats the idea of not having a control arm in clinical trials. Unfortunately the cost in money and lives of having a control arm is the difference between science and superstition.
Follow
@pfh I think though, it's important to contextualise this. There are situations (e.g. in oncology, or like in the article rare disease and personalised medicine) where one-armed trials have a place. I don't think anyone is advocating ditching controls in general. It's a fine line to walk, though, I agree.
